TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
Brief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)


Options:
A: Intervention Type: DRUG; Name: pamidronate; Assigned to Arm(s): N/A
B: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
C: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
D: Arm Label: Thalidomide + Bisphosphonate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate, Drug: Thalidomide, Drug: Zometa | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Thalidomide + Bisphosphonate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)
Brief Summary: To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.


Options:
A: Arm Label: Telmisartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan | Arm Label: Telmisartan/hydrochlorothiazide; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/hydrochlorothiazide | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Telmisartan/hydrochlorothiazide
B: Intervention Type: DRUG; Name: Amlodipine/Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
D: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan
Brief Summary: In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
B: Arm Label: Eurartesim (control); Type: OTHER; Interventions: Drug: DHA-PPQ | Arm Label: Primaquine 0.75mg base/kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.75) | Arm Label: Primaquine 0.4mg base /kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.4) | Arm Label: Primaquine 0.2mg base/kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.2) | Intervention Type: DRUG; Name: DHA-PPQ; Assigned to Arm(s): Eurartesim (control), Primaquine 0.2mg base/kg, Primaquine 0.4mg base /kg, Primaquine 0.75mg base/kg | Intervention Type: DRUG; Name: PQ (0.75); Assigned to Arm(s): Primaquine 0.75mg base/kg | Intervention Type: DRUG; Name: PQ (0.4); Assigned to Arm(s): Primaquine 0.4mg base /kg | Intervention Type: DRUG; Name: PQ (0.2); Assigned to Arm(s): Primaquine 0.2mg base/kg
C: Arm Label: 3 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Arm Label: 2 day therapy; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin piperaquine; Assigned to Arm(s): 2 day therapy, 3 day therapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan
Brief Summary: In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
D: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan
Brief Summary: In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): Arm 1
B: Arm Label: CQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ) | Arm Label: CQ+PQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ), Drug: primaquine (PQ) | Arm Label: CQ + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: Chloroquine (CQ) | Arm Label: SP; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP) | Arm Label: SP + PQ; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP), Drug: primaquine (PQ) | Arm Label: SP + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: sulphadoxine-pyrimethamine (SP) | Intervention Type: DRUG; Name: artesunate (AS); Assigned to Arm(s): CQ + AS, SP + AS | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine (SP); Assigned to Arm(s): SP, SP + AS, SP + PQ | Intervention Type: DRUG; Name: Chloroquine (CQ); Assigned to Arm(s): CQ, CQ + AS, CQ+PQ | Intervention Type: DRUG; Name: primaquine (PQ); Assigned to Arm(s): CQ+PQ, SP + PQ
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) in Children With Acute Falciparum Malaria
Brief Summary: The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.


Options:
A: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
B: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
C: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
D: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) in Children With Acute Falciparum Malaria
Brief Summary: The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.


Options:
A: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
D: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) in Children With Acute Falciparum Malaria
Brief Summary: The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.


Options:
A: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
D: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Training and Depression in Older Adults II
Brief Summary: This study will evaluate the effectiveness of both center-based and home-based exercise versus the antidepressant drug sertraline in treating depression in middle-aged and older adults.


Options:
A: Intervention Type: BEHAVIORAL; Name: Supervised Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-Based Exercise; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline (Zoloft); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A
C: Arm Label: A; Type: OTHER; Interventions: Other: supervised training | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: supervised training; Assigned to Arm(s): A
D: Arm Label: Non-Exercise Control Group; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 4-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 8-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 12-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 12-kcal/kg Energy Expenditure per week, 4-kcal/kg Energy Expenditure per week, 8-kcal/kg Energy Expenditure per week, Non-Exercise Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer
Brief Summary: RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effective in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying several different radiation therapy regimens to compare how well they work in treating patients with stage II prostate cancer.


Options:
A: Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Gray | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Radiation: Gray | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 2
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 70 Gy, Drug: Androgen blockade | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 76 Gy, Drug: Androgen blockade | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy 76 Gy | Intervention Type: RADIATION; Name: Radiotherapy 70 Gy; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: Radiotherapy 76 Gy; Assigned to Arm(s): Arm 2, Arm 3 | Intervention Type: DRUG; Name: Androgen blockade; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: Conventional 3D-CRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional 3D-CRT or IMRT | Arm Label: Hypofractionated 3D-CRT; Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated 3D-CRT or IMRT | Intervention Type: RADIATION; Name: Conventional 3D-CRT or IMRT; Assigned to Arm(s): Conventional 3D-CRT | Intervention Type: RADIATION; Name: Hypofractionated 3D-CRT or IMRT; Assigned to Arm(s): Hypofractionated 3D-CRT

Answer: D